Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  daratumumab
Find trials that include:  Any drugs shown
Results 1-7 of 7 for your search:
Start Over
Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma
Phase: Phase IV
Type: Treatment
Age: 18 and over
Trial IDs: CR106626, NCI-2015-01138, 54767414MMY3010, NCT02477891
A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CR103663, NCI-2014-01352, 2013-005525-23, 54767414MMY3003, NCT02076009
Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CR103995, NCI-2014-02437, 2014-000255-85, 54767414MMY3004, NCT02136134
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CR104762, NCI-2015-01114, 2014-002273-11, 54767414MMY3008, NCT02252172
A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CR106449, NCI-2015-01089, 2014-005139-14, 54767414SMM2001, NCT02316106
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CR103015, NCI-2014-02217, 2013-003491-12, 54767414MMY1001, NCT01998971
Start Over